Phase III Data Support Chemo-Free Approach to ALL.

In the phase III GIMEMA ALL2820 trial, treatment with ponatinib and blinatumomab led to significantly better response rates and overall survival than a chemotherapy-imatinib regimen for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. The findings could change the standard of care for the disease.